Reports received by FDA, by month

November 2007: adverse event reports received by FDA

23,864 drug reports (FAERS) and 20,361 device reports (MAUDE).

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

23,864
drug reports received: 18,181 a year earlier; 21,615
monthly average, preceding 12 months: 10.4% against the average; 20,361
device reports received: 12,541 a year earlier

FDA received 23,864 drug adverse event reports in November 2007, against 18,181 in the same month a year earlier and a monthly average of 21,615 over the preceding 12 months. The MAUDE device database received 20,361 reports that month (12,541 a year earlier).

The drugs listed most often as suspect products were Byetta (3,007), Commit (1,169) and Fosamax (1,154), and the reactions recorded most often were blood glucose increased (1,843), nausea (1,829) and osteonecrosis (1,109).

Relative to their own average over the preceding 12 months, the drugs whose report count rose most were Coreg (12× its average), Coreg CR (11.2× its average) and Fosamax (11× its average). A jump in one month usually reflects a batch of reports from a manufacturer, a publicised event or a new product, not a change in what happens to patients.

Drug reports by month, three years to November 2007

Drugs listed most often as suspect products

Drug	Reports	Share of the month
Byetta	3,007	12.6%
Commit	1,169	4.9%
Fosamax	1,154	4.8%
Coreg	818	3.4%
Januvia	752	3.2%
Chantix	408	1.7%
Lipitor	399	1.7%
Tiotropium bromide	352	1.5%
Betaseron	325	1.4%
Levaquin	306	1.3%
Zyprexa	261	1.1%
Remicade	252	1.1%
Coreg CR	228	1%
Rozerem	226	0.9%
Enbrel	218	0.9%

FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Largest rises against their own average

Drug	Reports this month	Times its 12-month average
Coreg	818	12×
Coreg CR	228	11.2×
Fosamax	1,154	11×
Commit	1,169	10.1×
Exenatide Pen Disposable	122	8.5×
Dianeal	188	5×
Avandamet	155	4.5×
Zantac 150	56	4.2×

Drugs with at least 50 reports in the month and an average of at least 10 a month over the preceding year. A rise usually reflects a batch of manufacturer reports, a publicised event or a new product.

Reactions recorded most often

MedDRA term	Reports	Share of the month
Blood glucose increasedraised blood sugar reading	1,843	7.7%
Nauseafeeling sick	1,829	7.7%
Osteonecrosis	1,109	4.6%
Drug ineffectivethe medicine did not work as expected	1,029	4.3%
Dizzinesslight-headedness or unsteadiness	936	3.9%
Vomitingbeing sick	927	3.9%
Weight decreasedweight loss	873	3.7%
Headachehead pain	743	3.1%
Dyspnoeashortness of breath	739	3.1%
Fatiguetiredness	733	3.1%
Diarrhoealoose or frequent stools	725	3%
Malaisegeneral feeling of being unwell	628	2.6%
Astheniaweakness or lack of energy	549	2.3%
Blood glucose decreasedlow blood sugar reading	544	2.3%
Decreased appetitereduced appetite	525	2.2%

Devices named most often

Brand	Reports	Share of device reports
Freestyle Flash	2,033	10%
Freestyle	646	3.2%
Sprint Fidelis	516	2.5%
Accu-Chek Comfort Curve Test Strips	296	1.5%
Contak Renewal 3	293	1.4%
Cypher Sirolimus-Eluting Coronary Stent	197	1%
M Series	190	0.9%
Clearstar Pump	185	0.9%
Endotak Reliance G	164	0.8%
Taxus Express2 Paclitaxel-Eluting Coronary Stent System	149	0.7%

Questions about November 2007

How many adverse event reports did FDA receive in November 2007?

23,864 drug reports are in the openFDA FAERS release of 28 Sep 2026, and 20,361 device reports in the MAUDE release of 28 Sep 2026. The same month a year earlier has 18,181 drug reports.

Which drugs were listed most often?

Byetta (3,007), Commit (1,169), Fosamax (1,154), Coreg (818) and Januvia (752).

Which reactions were recorded most often?

blood glucose increased (1,843), nausea (1,829), osteonecrosis (1,109), drug ineffective (1,029) and dizziness (936).

Can the count for a month still change?

Yes. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Older months change little.

Does a busy month mean something happened that month?

Not by itself. The date is when FDA received the report, not when the event occurred, and volume follows manufacturer batches, product launches and publicity. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.